{"id":"NCT02720692","sponsor":"Baudax Bio","briefTitle":"Evaluation of N1539 Following Major Surgery","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety of N1539 Following Major Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2017-03","completion":"2017-05","firstPosted":"2016-03-28","resultsPosted":"2023-05-25","lastUpdate":"2023-06-22"},"enrollment":722,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain, Post-operative"],"interventions":[{"type":"DRUG","name":"N1539","otherNames":["Intravenous meloxicam"]},{"type":"DRUG","name":"Intravenous Placebo","otherNames":[]}],"arms":[{"label":"N1539 30mg","type":"EXPERIMENTAL"},{"label":"IV Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.","primaryOutcome":{"measure":"Number of Subjects With Adverse Events","timeFrame":"28 Days","effectByArm":[{"arm":"N1539 30 mg","deltaMin":339,"sd":null},{"arm":"IV Placebo","deltaMin":119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":32,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":["32021411","30786162","30737315"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":538},"commonTop":["Nausea","Constipation","Vomiting","Headache","Pruritus"]}}